EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseSystematische Übersicht

Oral anticoagulant therapy for patients with atrial fibrillation on long‐term dialysis: A network meta‐analysis of 137,574 patients

Yao Du iD, Yuwen Zeng, Sixin Xu, Qiwei Shen, Jinzhu Hu, Gregory Y H Lip iD

European Journal of Clinical Investigation · 2025

DOI: 10.1111/eci.70120 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift European Journal of Clinical Investigation, 2025. Verfasst von Yao Du und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China. Hauptthemen laut MEDLINE: Anticoagulants, Atrial Fibrillation, Ischemic Stroke, Kidney Failure, Chronic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Double Thousand Talents Project of Jiangxi Province, National Natural Science Foundation of China, Jiangxi Province's Main Discipline Academic and Technical Leader Training Program - Leading Talent Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with atrial fibrillation (AF) with end‐stage renal failure on renal replacement therapy are at high risk of stroke and bleeding, but the optimal oral anticoagulation (OAC) strategy is uncertain. To investigate the most effective OAC therapy for patients with AF on long‐term dialysis.

Methods

PubMed, EMBASE and Web of Science databases were systematically searched from inception to 9 October 2024 to identify relevant studies on OAC strategy for patients with AF on long‐term dialysis. The effectiveness outcomes were ischaemic stroke and/or systemic thromboembolism, all‐cause mortality and the safety endpoint was major bleeding.

Results

The present study encompassed a comprehensive analysis of 33 studies involving a total of 137,574 patients with AF on long‐term dialysis. All OACs, including warfarin (hazard ratio [HR], .963; 95% confidence interval [CI], .841–1.104), did not show a statistically significant decrease in the risk of ischaemic stroke and/or systemic thromboembolism compared to no anticoagulant therapy. Only apixaban 5 mg twice daily was associated with a lower risk of all‐cause mortality compared to non‐OAC use (HR, .671; 95% CI, .490–.919). Dabigatran (HR, 2.140; 95% CI, 1.734–2.642) and phenprocoumon (HR, 2.419; 95% CI, 1.241–4.713) were associated with a significantly higher risk of major bleeding than non‐OAC use.

Conclusions

All OACs were not associated with a reduced risk of ischaemic stroke and/or systemic thromboembolism in patients with AF on long‐term dialysis. Only apixaban 5 mg twice daily was associated with a decrease in all‐cause mortality when compared with non‐OAC use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsAtrial FibrillationIschemic StrokeKidney Failure, ChronicRenal DialysisThromboembolismHumansAdministration, OralDabigatranHemorrhagePhenprocoumonPyrazolesPyridonesRivaroxabanStrokeWarfarin

Stichwörter der Autor:innen

all‐cause mortalityanticoagulantatrial fibrillationdialysisnetwork meta‐analysis

Substanzen

AnticoagulantsapixabanDabigatranPhenprocoumonPyrazolesPyridonesRivaroxabanWarfarin

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
  • The First People's Hospital of Jiujiang, Jiujiang, Jiangxi, China.
  • Liverpool Centre for Cardiovascular Science, at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Medical University of Bialystok, Bialystok, Poland.

ORCID-Profile: Yao Du, Gregory Y H Lip

Förderung

  • Double Thousand Talents Project of Jiangxi Province
  • National Natural Science Foundation of China
  • Jiangxi Province's Main Discipline Academic and Technical Leader Training Program - Leading Talent Project

Zitieren

APA

Du, Y., Zeng, Y., Xu, S., Shen, Q., Hu, J., & Lip, G. Y. H. (2025). Oral anticoagulant therapy for patients with atrial fibrillation on long‐term dialysis: A network meta‐analysis of 137,574 patients. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70120

Vancouver

Du Y, Zeng Y, Xu S, Shen Q, Hu J, Lip GYH. Oral anticoagulant therapy for patients with atrial fibrillation on long‐term dialysis: A network meta‐analysis of 137,574 patients. European Journal of Clinical Investigation. 2025. doi:10.1111/eci.70120

BibTeX
@article{Du2025,
  author = {Du, Yao and Zeng, Yuwen and Xu, Sixin and Shen, Qiwei and Hu, Jinzhu and Lip, Gregory Y H},
  title = {Oral anticoagulant therapy for patients with atrial fibrillation on long‐term dialysis: A network meta‐analysis of 137,574 patients},
  journal = {European Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1111/eci.70120}
}
Kostenlos starten →